Autophagy Inhibitors Development Services for Bladder Cancer
The process of autophagy presents a promising avenue for targeting cancer cells, thereby opening up new possibilities in the field of potential therapeutic interventions, particularly in the multidisciplinary management of bladder cancer. Alfa Cytology delves into crucial cellular processes associated with cancer cell survival and therapy resistance, aiming to facilitate the discovery and optimization of novel autophagy inhibitors for bladder cancer therapy. This effort caters to a diverse range of research organizations and companies involved in therapeutic development.
Introduction to Autophagy Inhibitors
Autophagy plays a dual role in cancer, suppressing tumor initiation and aiding in tumor cell survival under stress. In bladder cancer (BC), autophagy helps maintain genomic integrity and prevent proliferation and inflammation during early stages. However, established tumors exploit autophagy to endure adverse conditions. Studies have shown that inhibiting key autophagy-related proteins like ATG7 can reduce bladder cancer invasiveness. The paradoxical nature of autophagy in cancer therapy makes it crucial to identify when and how to inhibit autophagy to enhance treatment efficacy.
Fig.1 Apoptosis-autophagy-tumor progression and recurrence triad and the dual role of autophagy for therapeutic purposes in cancer. (Konac, E., et al., 2021)
The development and application of autophagy inhibitors offer promising avenues for improving bladder cancer therapies.
|
Inhibitor |
Mechanism of action |
Treatments combined with inhibitor |
| Chloroquine |
Lysosomal lumen alkalizer |
Cisplatin, radiotherapy, lapatinib or gefitinib |
| 3-Methyladenine |
PI3K inhibitor |
Cisplatin, Fangchinoline, lapatinib or gefitinib |
| Icaritin |
Protein synthesis inhibitor |
Epirubicin |
| Frondoside A |
Protein synthesis inhibitor |
Cisplatin and gemcitabine |
| shRNA |
Knockdown of Beclin1 and ATG7/ATG12 |
Cisplatin |
| siRNA |
Suppression of ATG12 |
Lapatinib or gefitinib |
Our Services
With our extensive experience, specialized expertise, and dedicated team of professionals, Alfa Cytology aims to offer a comprehensive solution for the development of autophagy inhibitors and expedited translation of promising drug candidates.
Assay Development and High-Throughput Screening
Custom assay development and high-throughput screening to identify potent autophagy inhibitors.
Mechanistic Studies
Detailed studies to elucidate the mechanism of action of potential autophagy inhibitors.
Custom assay development and high-throughput screening to identify potent autophagy inhibitors.
Contact Us
Choose Alfa Cytology's expertise in autophagy inhibitor development to enhance your bladder cancer research. Our dedicated team and advanced capabilities ensure tailored solutions to meet your specific needs. Contact us today to learn how we can support your autophagy inhibitor development projects and drive your research forward with precision and excellence.
Reference
- Konac, E., Kurman, Y., & Baltaci, S. Contrast effects of autophagy in the treatment of bladder cancer. Experimental biology and medicine (Maywood, N.J.), 2021, 246(3), 354–367.
For research use only. Not intended for any clinical use.
Related Services
